Teleflex (NYSE:TFX) Announces Earnings Results

Teleflex (NYSE:TFX) issued its quarterly earnings results on Thursday. The medical technology company reported $3.67 earnings per share for the quarter, beating analysts’ consensus estimates of $3.38 by $0.29, Zacks reports. The company had revenue of $892.90 million during the quarter, compared to the consensus estimate of $892.79 million. Teleflex had a net margin of 6.31% and a return on equity of 15.08%. Teleflex’s revenue was up 19.4% on a year-over-year basis. During the same period in the prior year, the company earned $3.49 EPS. Teleflex updated its FY 2025 guidance to 14.000-14.200 EPS.

Teleflex Price Performance

TFX opened at $109.39 on Friday. The firm has a market capitalization of $4.83 billion, a P/E ratio of 25.74, a PEG ratio of 1.79 and a beta of 1.05. The stock has a fifty day moving average of $125.66 and a 200-day moving average of $123.13. The company has a quick ratio of 1.44, a current ratio of 2.41 and a debt-to-equity ratio of 0.42. Teleflex has a 12-month low of $102.58 and a 12-month high of $200.15.

Teleflex Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, December 15th. Shareholders of record on Friday, November 14th will be paid a dividend of $0.34 per share. This represents a $1.36 annualized dividend and a yield of 1.2%. The ex-dividend date of this dividend is Friday, November 14th. Teleflex’s payout ratio is -18.50%.

Analyst Upgrades and Downgrades

A number of analysts recently commented on the stock. Weiss Ratings reiterated a “sell (d+)” rating on shares of Teleflex in a report on Wednesday, October 8th. Wall Street Zen cut Teleflex from a “strong-buy” rating to a “buy” rating in a report on Monday, September 15th. Zacks Research downgraded Teleflex from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 30th. Mizuho lifted their target price on Teleflex from $130.00 to $135.00 and gave the stock a “neutral” rating in a report on Friday, August 1st. Finally, Wells Fargo & Company cut their target price on Teleflex from $131.00 to $114.00 and set an “equal weight” rating on the stock in a research report on Friday. One investment analyst has rated the stock with a Buy rating, nine have given a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Reduce” and an average target price of $137.00.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the business. Merit Financial Group LLC lifted its position in shares of Teleflex by 227.8% in the third quarter. Merit Financial Group LLC now owns 10,588 shares of the medical technology company’s stock worth $1,296,000 after purchasing an additional 7,358 shares in the last quarter. Daiwa Securities Group Inc. increased its stake in Teleflex by 71.9% in the 2nd quarter. Daiwa Securities Group Inc. now owns 9,342 shares of the medical technology company’s stock valued at $1,106,000 after buying an additional 3,907 shares during the period. Jump Financial LLC acquired a new position in Teleflex in the 2nd quarter valued at approximately $987,000. Tidal Investments LLC lifted its position in Teleflex by 26.2% in the 2nd quarter. Tidal Investments LLC now owns 7,563 shares of the medical technology company’s stock worth $895,000 after buying an additional 1,571 shares in the last quarter. Finally, Jane Street Group LLC boosted its stake in shares of Teleflex by 42.6% during the 1st quarter. Jane Street Group LLC now owns 6,343 shares of the medical technology company’s stock valued at $877,000 after buying an additional 1,895 shares during the period. 95.62% of the stock is owned by institutional investors and hedge funds.

Teleflex Company Profile

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.